Methylation of specific histone residues is capable of both gene activation and silencing. Despite vast work on the function of methylation, most studies either present a static snapshot of methylation or fail to assign kinetic information to specific residues. Using liquid chromatography-tandem mass spectrometry on a high-resolution mass spectrometer and heavy methyl-SILAC labeling, we studied site-specific histone lysine and arginine methylation dynamics. The detection of labeled intermediates within a methylation state revealed that mono-, di-, and trimethylated residues generally have progressively slower rates of formation. Furthermore, methylations associated with active genes have faster rates than methylations associated with silent genes. Finally, the presence of both an active and silencing mark on the same peptide results in a slower rate of methylation than the presence of either mark alone. Here we show that quantitative proteomic approaches such as this can determine the dynamics of multiple methylated residues, an understudied portion of histone biology.

Histones are decorated extensively with numerous post-translational modifications (PTMs) on several different residues (1). Located mostly in the unstructured N-terminal tails, these PTMs influence the expression of genes bound to the histones by the recruitment or displacement of non-histone transcriptional or regulatory proteins (2). Lysine methylation is notable among histone PTMs for its diversity of forms and for its binary-like influence over gene expression. Methyltransferases and demethylases catalyze specific conversions between unmodified (me0), mono- (me1), di- (me2), and trimethylation (me3) states. For instance, while G9a and Suw39h1 direct histone H3 lysine 9 (H3K9) me1/me2 and me3 production, respectively (3), JHDM2A (4), and JHDM3A (5) promote demethylation of H3K9me2 and H3K9me3, respectively. The binary influence on gene expression can be illustrated with chromatin immunoprecipitation (ChIP) studies that revealed H3K4 to be enriched in euchromatic regions and H3K9 in heterochromatic regions (6). Another residue that can be mono- and dimethylated on histones is arginine. Furthermore, whereas H4R3 methylation (7) and H3R2me1 (8) are associated with gene activation, H3R2me2 is associated with gene silencing (8).

These features suggest that histone lysine and arginine methylations are dynamically regulated processes. Nevertheless, most studies present histone methylation as a static condition at a particular time, with little regard to turnover or dynamics of the PTM. Indeed, the inability to resolve between transient and more long-lived methylations likely contributed to the traditional conception of histone methylation as irreversible (9). Past studies have used radiolabeling to track methylation turnover on a non-residue specific basis (10, 11) and other studies monitored the correlation between histone methylation and cell cycle progression (12–14), including a recent report (15) that tracked the modification profile of newly synthesized histones. For example, Pesavento et al. reported that newly synthesized H4 becomes progressively methylated at Lys-20 during the cell cycle (13). Additionally, McManus et al. (14) reported that levels of H3K9me1, me2, and me3 increase from interphase to metaphase, and decrease to initial levels at the start of the next mitotic cycle.

To our knowledge, there is no report of a quantitative model characterizing the steady-state kinetics of global methylation on a residue-specific basis. The development of methods to investigate methylation kinetics would elucidate the mechanisms by which this PTM can temporally and dynamically regulate gene expression and provide a sensitive metric to distinguish cells in different physiological states. The importance of understanding the dynamics of histone methylation is illustrated with past studies demonstrating that the shift from H3K4me2 and H3K36me2/3 to H3K4me3 and H3K79me2 defined the temporal transition from RNA polymerase II binding to release for transcript elongation (16).

To this end, we applied heavy methyl stable isotope labeling by amino acids in cell culture (SILAC) (17) to quantitatively probe the rates of histone methylation on a residue-specific basis in HeLa cells (Fig. 1A). The method relies on mass spectrometry (18) to detect the in vivo incorporation of labeled 13C4-methionine, which is metabolized from exogenous 13C4-methionine, to methylation substrates. Using heavy methyl SILAC to quantify histone methylation dynamics, we report that different lysine and arginine residues, and different methylation states within the same residue, have different rates of formation. This and other findings in our studies advance the current understanding of histone methylation and provide a platform for further research into the dynamics of histone PTMs.

**EXPERIMENTAL PROCEDURES**

*Cell Culture and SILAC—Throughout the experiment except during the transition into different media and sample*
Histone Methylation Dynamics Studied by MS

A  PTM Turnover MS

B  Unmodified

Unmodified

k_{0-1}  \quad k_{1-0}  \quad k_{2-1}  \quad k_{3-2}  \quad k_{2-3}  \quad k_{1-2}

k_{1-0}  \quad k_{2-1}  \quad k_{3-2}  \quad k_{2-3}  \quad k_{1-2}

k_{2-1}  \quad k_{3-2}  \quad k_{2-3}  \quad k_{1-2}

m/z

"old"  \quad "new"

FIGURE 1. Schematic of experimental design for heavy methyl SILAC. A, suspension HeLa cultures were introduced into 13CD_{3}-methionine supplemented media to allow for incorporation of the 13CD_{3} label (white) onto the methyl groups on histones. The labeled methyl can be distinguished from the unlabeled methyl (gray) using MS (4 Da shift per methyl incorporation). B, application of heavy methyl SILAC can be used to unravel methylation dynamics, as depicted in our idealized system. Gray hexagons indicate unlabeled "old" methyl, and white hexagons indicate labeled "new" methyl groups.

collection, HeLa cells were maintained at 37 °C in 0.2 LPM CO_{2}. Suspension cultures were initially maintained in minimum essential Joklik modified medium (SAFC Biosciences, KS) supplemented with 10% newborn calf serum (HyClone, UT), penicillin, streptomycin, and 1% GlutaMAX (Invitrogen). For the time course experiments, cultures were pelleted at 80 rcf in a refrigerated tabletop centrifuge. After decanting the media, cells were resuspended with Joklik media depleted of unlabeled methionine (HyClone) and supplemented with L-methionine-13C_{6} (Sigma-Aldrich), which we term "labeled media." We ran a parallel experiment with media supplemented with L-lysine-13C_{6} (Cambridge Isotope Laboratories Inc.) to determine the turnover for histone H1.4. The labeled media was supplemented with 5% dialyzed fetal bovine serum (Invitrogen), penicillin, streptomycin, and 1% GlutaMAX. Daily aliquots were taken for 7 days, and media was replenished everyday to maintain a cell density of 2–6 × 10^{5} cells/ml throughout the experiment. Cells were pelleted at 600 rcf and washed in phosphate-buffered saline. The pellets were flash frozen and stored at −80 °C.

Histone Preparation for MS—Histones were isolated from cells as described in Ref. 19 and derivatized with propionic anhydride as described in Ref. 20. After derivatization, samples were diluted in 0.1% acetic acid for desalting before MS analysis using homemade C18 STAGE tips as previously described (21).

MS Analysis—Samples were loaded by an Eksigent AS2 autosampler onto 75 μm ID fused silica capillary columns packed with 15 cm of C18-reversed phase resin (Magic C18, 5 μm particles, 200 Å pore size, Michrom BioResources) and constructed with an electrospray tip for nanoflow reversed-phase high performance liquid chromatography tandem mass spectrometry on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer (Thermo Electron). Peptides were resolved with a gradient from 5 to 35% Buffer B in a 110-min gradient (Buffer A: 0.1 M acetic acid, Buffer B: 70% acetonitrile in 0.1 M acetic acid) with a flow rate of ~200 nl/min on an Agilent 1200 binary HPLC system. The Orbitrap was operated in data-dependent mode with a resolution of 30,000 for a full MS spectrum and 7 subsequent MS/MS spectra collected in the ion trap of fragments produced by collision-induced dissociation. To reduce duplicate MS/MS spectra, peptides selected for MS/MS interrogation were placed on an exclusion list for 30 s.

Peptide Quantification—All MS and MS/MS spectra were analyzed with Qual Browser (version 2.0.7, Thermo Scientific), and peptide abundances were obtained by chromatographic peak integration. Identities of all peptides were confirmed by manual inspection of MS/MS spectra (supplemental Fig. S1), and a list of all peptides quantified is provided (supplemental Table S1).

To describe unambiguously a specific methylated species, we denote each residue with X-Y, where X is the number of total methyls, and Y is the number of labeled methyls. For instance, H3K36me1:0 refers to unlabeled monomethylated H3K36, and H3K36me1:1 refers to labeled monomethylated H3K36. We define “methylation states” as the distinction between me1, me2, and me3, and “labeled intermediates” as the different degrees of labeling within states.

The relative abundances were calculated two ways, differing in what is considered the “total pool.” In the first method, the “total pool” represents all the methylation intermediates for a specific methylation state of a particular residue. Thus, the abundance of H3K36me1:0 would be determined with respect to H3K36me1:0 and me1:1. This reveals the distribution of differently labeled species within a methylation state and is more robust to variable ionization efficiencies of different methylation states within and between peptides. We justify the calculation with the logic that growth conditions should not change with 12CH_{3}- or 13CD_{3}-methionine, and that the total abundance of each methylated species does not change. For instance, the percentage of total H3 peptides monomethylated on Lys-36 should not change during the time course, but rather the distribution of labeled intermediates within the me1 state. We term values calculated from such a method as “relative distribution.” This was used to quantify half-maximal times of the formation of labeled peptides (t_{1/2}), as described in supplemental Fig. S2. The half-maximal time provides a single measure of how quickly a particular species is formed, and thus is predictive of the overall rate of methylation for that species.

In the second method, the “total pool” represents all methylation states and intermediates on the tryptic digest fragment. Thus, the abundance of H3K79me1:0 would be determined with respect to H3K79me1:0, me1:1, me2:0, me2:1, and me2:2. This provides a more accurate comparison of abundances...
between different methylation states. We term values calculated from such a method as “relative levels,” and this was used for extrapolating kinetic parameters. Both “relative distribution” and “relative levels” are unit-less variables.

Kinetics Modeling—To quantify relative distributions, we applied another differential equation (supplemental Fig. S2), to determine the half-maximal times of the formation of the fully labeled species and used a Wilcoxon rank sum and Kruskal-Wallis test to compare half-maximal times between active and silencing marks. Relative distributions of the labeled methylation states and $^{13}$CD$_3$-methionine incorporated protein from each replicate were fitted with MATLAB (7.8.0) (supplemental data and Fig. S1).

To quantify relative levels, we derived a set of first order differential equations (supplemental Fig. S2) to characterize the dynamics of methylated residues in an idealized system (Fig. 1B). The parameters are the rate of unmodified histones becoming bound to chromatin ($k_{p0}$), sequential addition of a labeled methyl ($k_{13}1$, $k_{12}$, $k_{23}$), sequential demethylation ($k_{32}$, $k_{21}$, $k_{10}$), and histone degradation for each methylation state ($k_{p0}$, $k_{13}1$, $k_{23}$, $k_{32}$) respectively. Additionally, not all peptides necessarily acquire a $^{13}$CD$_3$ methyl group, as $^{12}$CH$_3$ from unlabeled methionine resulting from macromolecule decomposition contributes to the sequential methylation. Thus, parameters ($k'_{p0}$, $k'_{13}1$, $k'_{23}$, $k'_{32}$), for the unlabeled methyl contribution are also considered.

Relative levels of all the species were fitted to the appropriate differential equations using MATLAB (7.8.0) (supplemental data and Fig. S2). Certain constraints were set to avoid non-biologically reasonable parameter values. In particular, none of the parameters could be less than 0. Additionally, all $\mu$ were set to be $\geq \ln(2)$, which is the expected dilution rate resulting from cell division. After each of the 1000–10000 iterations of the program, a set of parameters is produced that minimizes the root mean squared difference (RMSD) between the observed data, and the expected solutions of the equations with the determined parameters. In the entire parameter space determined, we averaged only the sets of parameters that did not produce a RMSD greater than 125% of the minimum RMSD.

RESULTS

Effect of $^{13}$CD$_3$-Methionine Isotope on Cell Physiology and General Histone Protein Turnover Rates—To track and quantify newly methylated histones, we cultured HeLa cells in media with $^{13}$CD$_3$-methionine. HeLa cell morphology appeared normal throughout the time course, indicating that the presence of the heavy isotope itself does not affect the biology of our system. Because most newly synthesized core histones H3 and H4 during S phase (23) incorporate the labeled methionine (13CD$_3$, 4 Da shift per methyl group incorporation), half-maximal labeling for all histones should occur after one mitotic cycle. The rate of label incorporation was determined by examining the peptides from H1.4 (residues 33–53, KASGPPVSELITKAVAASKER) H3 (residues 117–128, VTIMPKDIQLAR) and H4 (residues 79–92, KTVTAMDVVYALKR) (Fig. 2). The peptides mentioned above for H3 and H4 will incorporate a single labeled methionine during protein synthesis after incubation in the labeled $^{13}$CD$_3$-methionine media and thus can be monitored for protein turnover. In Fig. 2A, we observed a peak at 748.932 m/z corresponding to the “old” unlabeled H3 117–128 peptide signal, and after 1 day, observed that this peptide signal

**FIGURE 2.** Monitoring general protein methylation rates on histones by MS. Full mass spectra of the [M+2H]$^{2+}$ ions of the old unlabeled (charge = +2, with the molecular ion carrying two additional protons) containing H3 and H4 peptides (A and B) and newly synthesized peptides (C and D) that incorporate heavy $^{13}$CD$_3$-methionine after 1 day of introduction into labeled media. Note that after 1 day, nearly equal abundances for the isotopic distributions corresponding to the “old” and “new” synthesized peptide are observed, pr, propionyl amide group from chemical derivatization of histone proteins.
Histone Methylation Dynamics Studied by MS

**TABLE 1**
The average half-maximal times ($t_{1/2}$) of fully labeled histones

Although the H3K9 data combine the relative abundances of the peptide regardless of Lys-14 acetylation, the Lys-27 and Lys-36 data do not combine the relative abundance from peptides that are also modified at Lys-36 or Lys-27, respectively. These values, S, indicate the variability to a single peptide within the same SILAC experiment. However, the variability between replicates was high, with the overall standard deviation of the three replicates was 1.29.

| PTM       | $t_{1/2}$ (h) | S.E.      | Type  | PTM       | $t_{1/2}$ (h) | S.E.      | Type  |
|-----------|--------------|-----------|-------|-----------|--------------|-----------|-------|
| Overall H3 | 1.298        | 0.007     |       | H3K9me1:1 | 0.959        | 0.129     |       |
| H3K9me1:1 | 0.959        | 0.129     |       | H3K9me2:2 | 1.031        | 0.060     | S(33) |
| H3K9me3:3 | 1.344        | 0.339     |       | H3K18me1:1| 1.207        | 0.116     | N     |
| H3K27me1:1| 0.470        | 0.005     |       | H4K20me1:1| 0.297        | 0.005     | A(33) |
| H3K27me2:2| 1.145        | 0.001     |       | H4K20me3:3| 4.809        | 1.483     | S(34) |
| H3K27me3:3| 3.128        | 0.032     |       | Overall H4| 1.385        | 0.072     |       |
| H3K36me1:1| 0.751        | 0.085     |       | H1.4      | 1.264        | 0.166     |       |

**FIGURE 3.** Overall protein turnover rates of histones H3, H4, and H1.4. A, relative distributions of the formation of the newly synthesized H1.4 (triangle), H3 (circle), and H4 (square) peptides that contain either a heavy \[1^{3}CD_{3}\]-methionine (H3 and H4) or L-lysine-13C_{6} (H1.4) isotope during the time course (days). The calculation of relative distributions is described in the text. B, average half-maximal time of the H1.4, H3, H4 peptides, with vertical bars indicating the S.E.  

Although the H3K9 data combine the relative abundances of the peptide regardless of Lys-14 acetylation, the Lys-27 and Lys-36 data do not combine the relative abundance from peptides that are also modified at Lys-36 or Lys-27, respectively. A, active; S, silent, and n, not definitively determined for specific methylation state of the residue.

is decreasing concurrently with the appearance of the “new” synthesized and isotopically labeled peptide at 750.945 ± 1 Da shift (Fig. 2C). Similarly, signals corresponding to the “old” and “new” H4 79–92 peptide can be detected at 881.998 and 884.010 ± 1 Da shifts, respectively, as well (Fig. 2, B and D).

As histone H1 variants do not contain methionine, we used a different SILAC experiment to monitor turnover of histone H1.4. For H1.4, we labeled cells with isotopically heavy lysine (\[^{15}N_{2}\]^{13}C_{6}-lysine), and thus could monitor protein turnover of the H1 variant by analysis of many peptides. We chose the fully lysine labeled peptide 33–53 for estimation of H1.4 turnover (Fig. 2B), for which we detected at 525.329 ± 1 Da shift on a charged peptide. In Fig. 2A, we see at Day 0 the peptide signal coming only from the unlabeled “old” H3K9me1:0 peptide at 542.312 m/z, and as we progress through subsequent days in labeled media, we detect an increase in the “new” labeled H3K9me1:1 peptide at 544.324 m/z as expected (+4 Da shift on a +2 charged peptide equals net +2 Da shift observed), and a decrease in the “old” H3K9me1:0 peptide.

However, we made an interesting observation when analyzing MS data of H3K9me2 and H3K9me3 peptides. As shown in Fig. 4B, we detected the unlabeled “old” H3K9me2:0 peptide at 521.306 m/z at Day 0, and upon incubation of cells in the labeled media we detected an increase in the fully labeled “new” H3K9me2:2 peptide at 525.329 (+8 Da shift on a +2 charged peptide equals net +4 Da m/z shift) over several days. We also detected another peak at 523.318 m/z (Day 1) that co-eluted
with the two other H3K9me2 peptides. Similarly, we also detected the “old” H3K9me3:0 peptide at 528.314 m/z and the newly fully labeled H3K9me3:3 peptide at 534.347 m/z (Fig. 4C). However, we detected two peaks at 530.325 and 532.335 m/z, respectively, that also co-elute with the unlabeled and fully labeled H3K9me3 peptides. We performed MS/MS experiments on these peptides, as shown in Fig. 5 for the peptide at 523.318 m/z co-eluting with the H3K9me2 peptides, and found these peptides possessed both unlabeled and labeled methyl groups on the Lys-9 residue. Fig. 5 displays the MS/MS spectrum for the 523.318 m/z species, and the fragmentation pattern is consistent with Lys-9 containing both one unlabeled and one labeled methyl group (b1 ion at 217 Da). We reasoned that this peptide originated from an H3 protein that was previously monomethylated on Lys-9, and was methylated to the dimethyl state after transfer into the 13CD3-labeled Joklik media. This methylated peptide represents an “intermediate” species that would have been missed by any other approach. In our quantitative analysis below, we also consider pathways where demethylation could lead to labeled intermediates.

Additionally, the two “intermediate” H3K9me3 species at 530.325 and 532.335 m/z, respectively, were determined after MS/MS experiments (supplemental Table S1 and Fig. S2) to be H3K9me3 peptides containing 2 “old” and 1 “new” methyl labels, and 1 “old” and 2 “new” methyl labels, respectively. In other words, the species at 530.325 m/z was an H3K9me2 peptide that was progressively methylated to the trimethyl state, while the species at 532.335 m/z was an H3K9me1 peptide that was progressively methylated to the trimethyl state. In addition to H3K9, we monitored the methylation status of histone H3K4, H3K18, H3K27, H3K36, H3K79, H4R3, H4K20, and H1.4K25 (supplemental Fig. S3). Thus, our method is useful both for monitoring the disappearance of the old methylated histones and appearance of the newly methylated histones, and for tracking any “intermediate” species that indicate progressive methylation in histone dynamics.

Methylation Rates within and between Residues—Using the methodology outlined above, we plotted the abundance of the peptides corresponding to the disappearance of “old” methylation, synthesis of “new” methylation and any “intermediate” methylation species for the H3, H4, and H1 residues. Fig. 6 shows the relative distribution of the three H3K9me2-labeled species. The H3K9me2:0 peptide is nearly completely gone by Day 7. H3K9me2:2 increases in abundance and reaches an asymptote of over 80%, while the “intermediate” H3K9me2:1 reaches a maximum at Day 1 and levels off in abundance over several days. The H3K9me2:2 peptide does not reach 100% abundance because of methylation from the unlabeled intracellular methionine pool; if the cells continued to grow in the labeled media, we expect that eventually this pool will become labeled and the H3K9me2:2 peptide should reach 100% abundance. The intermediate species often have different rates than
“old” or “new” methyl peptides. As previously mentioned for H3K9me2 (Fig. 6), H3K9me2:2 becomes the primary labeled species with the me2 state by Day 2 and levels off in abundance after Day 3. The trend that the fully labeled species within a methylation state has the greatest relative abundance after the time course is observed for all residues analyzed (Fig. 6 and supplemental Fig. S4).

We next compared the methylation rates of labeled species on different histone methylation residues to general overall histone turnover as described in Fig. 2. For example, comparisons made with the fully labeled peptides for H3K9, H4K20, and H3K36 peptides are shown in Fig. 7. Among our findings is the difference in the rate of label incorporation between the three methylation states of H3K9 (Table 1). From quantifying half-maximal times, we find that H3K9me1 reaches its final fully labeled state faster than histone H3. H3K9me2 and H3K9me3 have similar half-maximal times, and both states have \( t_{1/2} \) similar to histone H3 (Table 1). A similar pattern for each of the H4K20 methylation states was also observed, where H4K20me2 has a similar \( t_{1/2} \) as overall histone H4 protein as shown in Fig. 7B, consistent with previous evidence that H4K20 methylation does not appreciably turnover in vivo (14). In contrast, H3K36 methylation is much different, as both me1 and me2 have faster half-maximal rates than the histone H3 protein turnover (Fig. 7C and Table 1). Additionally, H3K27 methylation followed the overall trend of me1/H3K27me2/H3K27me3 (Table 1). The changes in \( t_{1/2} \) across different methylation states are not additive. For instance, H3K9me2 has a \( t_{1/2} \) nearly three times as long as H3K9me1, while H3K9me3 has a half-maximal time four times as long as H3K9me1. Thus, it is unlikely that differences in \( t_{1/2} \) between the methylation states are due to the additional time required to sequentially add methyl groups to a single residue.

Half-maximal times for all methylation sites detected on histones H3, H4, and H1.4 are listed in Table 1.

After quantifying \( t_{1/2} \) and categorizing the residues by their known epigenetic function, we observed that the silencing marks H3K27me3:3 and H4K20me3:3 have the slowest rates of all residues examined (Table 1). Our study also revealed the active mark H3K9me1 as having among the fastest rates. Indeed, active marks had significantly faster half-maximal times than repressive marks \( (p = 0.0200) \). The relative distributions of all labeled intermediates and fully labeled species for each histone peptide compared with overall turnover are shown in supplemental Fig. S4.
Influence of Multiple PTMs on Methylation Rates—When calculating the relative distributions for each labeled species, we combined the relative abundances of all the peptides that had the particular modification of interest without regard to modifications on other residues on the same peptide. This pertains to the H3 peptide KSTGGKAPR where both H3K9 can be methylated and K14 can be acetylated. When we deconvoluted the relative abundance for a labeled species into its two components, differing by Lys-14 acetylation, we observed that the rate of formation of H3K9me1:1 is increased by over 50% when Lys-14 is acetylated (Fig. 8 and supplemental Table S2). No significant change was observed for H3K9me2 when Lys-14 is acetylated (supplemental Fig. S5A). When we examined the influence of H3K27 and H3K36 on each other, the formation of H3K27me1, H3K27me2, and H3K36me1 and H3K36me2 is slower when the other residue becomes progressively methylated (supplemental Table S2 and Fig. S5B). In further investigating this effect for PTM combinations with 3 methylation states, namely H3K27me1, H3K36me1 and H3K36me2, there was a significant increase in $t_{1/2}$ with increasing methylation of Lys-36 and Lys-27 respectively ($p = 0.0329, df = 11$).

Kinetic Parameter Estimation from Differential Equations—In addition to calculating $t_{1/2}$, we quantified the dynamics for each methylation state (Fig. 1B) by estimating various parameters that represented first order rate constants (day$^{-1}$) in our idealized system for each residue (Table 2). This was attained by deriving a set of differential equations aimed at characterizing the dynamics of methylated residues (supplemental Fig. S2). The individual parameters derived from the relative levels are consistent with the qualitative conclusions drawn from the relative distributions. For instance, the trend that $k_{0_{-1}} > k_{1_{-2}} > k_{2_{-3}}$ for H3K9, H3K27, and H4K20 is consistent with the observation that me1, me2, and me3 peptides have progressively slower rates of formation (Table 2). Finally, the contribution of unlabeled methyl groups derived from macromolecule degradation ($k_{0_{-1}}, k_{1_{-2}}, k_{2_{-3}}$) was generally lower than the contribution from the labeled methyl groups ($k_{0_{-1}}, k_{1_{-2}}, k_{2_{-3}}$) across all residues. This reflects the fact that the levels of exogenous labeled methionine are greater than the levels of endogenous unlabeled methionine.

DISCUSSION

We performed heavy methyl SILAC with the goal of quantifying methylation rates for distinct histone residues. One advantage of this approach is the unbiased and direct detection of histone PTMs, in contrast to earlier 15N labeling methods that require an a priori knowledge of which proteins are modified (28). The versatility of heavy methyl SILAC has been demonstrated in studies that differentiate histone demethylation and histone turnover as possibilities to account for reduced levels of H3K9me3 (29). Whereas a pulse-chase analysis determines the fates of only the histones modified and synthesized during the pulse, it requires an additional media transfer step, is less robust toward noise in label detection, and does not provide significantly more information than a continuous pulse labeling approach with regard to steady state kinetics.

In addition to detection of the unlabeled and fully labeled methyl species, our experiments revealed the presence of labeled progressively methylated “intermediates” for the di-
Histone Methylation Dynamics Studied by MS

TABLE 2
Average kinetic parameters (day$^{-1}$) determined from fits of differential equations to the relative levels of various histone modifications

| Parameters | H3K4 | H3K18 | H4R3 | H1.4K26 | H3K36 | H3K79 | H3K9 | H3K27 | H4K20 |
|------------|------|-------|------|---------|-------|-------|------|-------|-------|
| $\alpha$   | 0.6948 (0.0016) | 1.4611 (0.2633) | 1.9590 (1.1634) | 2.8488 (1.0027) | 0.2539 (0.0750) | 0.7088 (0.0977) | 0.9453 (0.2226) | 0.3848 (0.0540) | 0.8118 (0.1372) |
| $k_{o}^{-1}$ | 0.0939 (0.0016) | 0.0052 (0.0008) | 0.0117 (0.0015) | 0.0223 (0.0010) | 3.4092 (0.4868) | 0.1186 (0.0777) | 3.8746 (0.1482) | 7.0139 (0.7200) | 3.8327 (0.1048) |
| $k_{+2}$   | 5.4056 (0.0277) | 0.2177 (0.0099) | 0.2220 (0.0038) | 4.1676 (0.0070) | 1.4813 (0.0123) | - | 5.4966 (0.0227) | 0.2177 (0.0099) | 0.2220 (0.0038) |
| $k_{+3}$   | 0.0200 (0.0007) | 0.0023 (0.0004) | 0.0019 (0.0006) | 0.0045 (0.0006) | 0.3104 (0.0520) | 0.0447 (0.0555) | 0.4320 (0.0229) | 1.0496 (0.1918) | 0.2212 (0.0186) |
| $k_{-2}$   | 0.3323 (0.0194) | 0.0094 (0.0069) | 0.2043 (0.0161) | 0.302 (0.0097) | 0.0302 (0.00118) | 0.101 (0.0002) | 0.101 (0.0002) | 0.101 (0.0002) | 0.101 (0.0002) |
| $k_{-3}$   | 0.0009 (0.0052) | 0.4943 (0.0188) | 0.1249 (0.1279) | 0.0401 (0.0422) | 1.2228 (0.4952) | 0.0125 (0.0308) | 0.2480 (0.2283) | 0.0016 (0.0084) | 0.0601 (0.0274) |
| $\mu_0$   | 0.0001 (0.0003) | 0.7704 (0.2633) | 1.2807 (1.1787) | 2.2330 (1.0385) | 3.2997 (1.7333) | 0.0171 (0.1193) | 0.6811 (1.1148) | 1.8727 (1.4989) | 0.7528 (0.8594) |
| $\mu_1$   | 0.0031 (0.0119) | 0.2834 (0.2406) | 0.1208 (0.0906) | 0.0374 (0.0315) | 2.6177 (1.2729) | 0.0221 (0.0447) | 0.7617 (0.2429) | 0.0047 (0.0396) | 0.0075 (0.0346) |
| $\mu_2$   | - | - | - | - | 0.3448 (0.0929) | 0.0061 (0.0476) | 0.0008 (0.0032) | 0.0000 (0.0007) | 0.0017 (0.0080) |
| $\mu_3$   | - | - | - | - | - | - | - | - | 0.0001 (0.0007) | 0.0003 (0.0045) | 0.2931 (0.4585) |

Non-processive: 

![Scheme 1](image)

Processive: 

![Scheme 2](image)

SCHEME 1. Consequences of processive and non-processive methylation. Non-processive, rather than processive, methylation from me1 to me3:2 should result in the observed appearance of the me2:1 peptide because of the detachment and rebinding of the methyltransferase after the first round of methylation to me2.

and trimethylated states. Such “intermediates” could link specific methyltransferases with a specific intermediate state. For instance, the formation of H3K9me3 can be catalyzed by Suv39H1, G9a, and SETDB1 (9). Yet, the three methyltransferases have different mechanisms. X-ray crystallographic analysis and in vitro assays have revealed that G9a (30) and the SET (31) domain act in a processive manner, where the enzyme can remain bound to the histone while subsequent methylations occur. In contrast, Suv39h1 is believed to act non-processively (32), where the enzyme must rebind to the histone after each round of methylation. We anticipate that the processive and non-processive mechanisms lead to different labeled intermediates (Scheme 1), which can be detected and resolved by our MS technique. Furthermore, the quantification of labeled intermediates at each residue allowed fitting to idealized differential equations and provided a more complete picture of how histone methylation is actively regulated in vivo. We observed some striking patterns in the MS data that warrant further discussion.

Methylation Rates of Active and Silencing Marks—

H3K27me3:3 and H4K20me3:3 have the slowest rates of formation among the histone PTMs examined. Interestingly, H3K27me3 (33) and H4K20me3 (34) are both silencing marks. The longer $t_{1/2}$ of these PTMs may reflect the inheritance of the epigenetic mark across mitotic cycles. For instance, H3K27me3 is maintained by the EED-EZH2 PcG complex and enriched on the inactivated X chromosome in stem cells (35). In embryonic stem cells, H3K27me3 localization rises to 50% maximal levels 1 day after differentiation, and then drops back to 50% at ~5 days after reaching the maximal abundance. These findings are broadly consistent with our value of $t_{1/2}$ for H3K27me3 in HeLa cells.

Another histone PTM associated with gene silencing is H4K20me3, which is localized to pericentric heterochromatin in Drosophila (34). Although H3K9me3 and H3K27me1 (36) have the same cytological localization as H4K20me3, our study found both of those PTMs have shorter half-maximal times than H4K20me3. Thus, H4K20me3 may represent a more stable PTM for pericentric heterochromatin formation. It is tempting to hypothesize that in bivalent chromatin domains containing both activating and silencing marks (37), the mark that is epistatic to the other may have a slower rate of formation. The techniques described in this report, combined with middle-down MS sequencing to detect simultaneously multiple PTMs on the same H3 polypeptide fragment, could test this hypothesis (19).

In contrast to H3K27me3 and H4K20me3, H3K9me1 has among the fastest half-maximal times. From the sites examined, we found that active marks are formed significantly faster than silencing marks. This suggests that cells require more fine temporal control over which genes are activated than which genes are silenced. Such a relation was proposed in a recent review, with the logic that silencing marks would be more easily perpetuated as epigenetic inheritance with slower turnovers (38). Although there might be exceptions, we can speculate the epigenetic features of certain PTMs based on their rate of formation. H3K18me1 is not known presently to be an active or silencing mark, but the PTM has a half-maximal time slower than all other me1 sites with gene activating function and similar to overall H3. Based on this trend, we hypothesize that H3K18me1 acts as a silencing mark. Additionally, because H3K18ac is highly correlated with active genes (39), our speculation that H3K18me1, which should be an antagonistic PTM to H3K18ac, acts as a silencing mark is not unreasonable, but this hypothesis requires further biological experiments to prove. Such behavior might also implicate H3K18me1 and H3K18ac1 and PTMs on other sites to act as “binary switches” on the same residue, similar to H3K9me3 and H3K9ac (40). It is important to note that our current data on histone methylation rates are averaged over the entire genome. The more
rapid histone exchange over specific genomic regions such as cis-regulatory elements (41) could influence the abundance of chromatin-bound histones. For instance, we predict that more rapid histone exchange leads to faster rates of formation of the labeled methylated species.

**Synergistic and Antagonistic Influences of Multiple PTMs—**In addition to finding different methylation rates between active and silencing marks, we found that the formation of H3K9me1.1 is increased when Lys-14 is acetylated. The behavior is consistent with our hypothesis that active marks are formed faster than silencing marks and with the finding that demethylation of H3K4 by LSD1 is inhibited by acetylation of H3K9, H3K14, and H3K18 (42). Because levels of H3K9me1 are a product of both methylation and demethylation, a decrease in demethylation due to H3K14ac could account for the increase in H3K9me1.1 levels. Further supporting evidence was found in a past report using a continuous pulse labeling with [3H]methionine in H3K9me1:1 levels. Further supporting evidence was found in demethylation due to H3K14ac could account for the increase in H3K9me1.1 levels. Further supporting evidence was found in a past report using a continuous pulse labeling with [3H]methionine in alfalfa histone H3.1 and H3.2 (10). The author proposed that increased acetylation relaxes the nucleosome to increase access for methyltransferases, although we found such a model unlikely given the spatial location of the H3 tails relative to the nucleosome (43).

In contrast to the synergistic effect of H3K14ac on H3K9me1, we believe that H3K27 and H3K36 may have antagonistic effects toward each other. In particular, the presence of another PTM on the same peptide with an opposite epigenetic effect may render the doubly modified peptide slower to form. Middle Down MS sequencing could reveal the effects of multiple PTMs on methylation rate (44). The histone code hypothesis proposes that combinatorial patterns of multiple histone PTMs lead to different transcriptional outputs (45). Thus, differences in peptide methylation rates observed due to PTMs on different residues may agree with such a model.

**Insights from Kinetic Modeling—**It is important to emphasize that the “rate constants” derived from our modeling do not reflect the activity of a specific methyltransferase or demethylase, but rather the average concerted activity of all the enzymes in vivo. Actual histone methylation dynamics are likely more complicated than our idealized system. For instance, we assumed sequential methylation and demethylation. In addition to the earlier examples for processive and non-processive methyltransferase, DIM-5 is a methyltransferase that sequentially methylates H3K9 to produce H3K9me2 and then H3K9me3 (46). However, ASH1 is known to trimethylate H3K9 from an unmodified state (22). Sequential methylation may likely not be the most accurate way to model such behavior. Although higher order differential equations could more accurately describe the enzymatically catalyzed methylation and demethylation, at least for overall H3 methylation, past studies found that turnover could indeed be modeled as a first order reaction (12).

Despite these caveats, the rates calculated from the relative levels are consistent with and provide a quantitative explanation for the half-maximal times from the relative distribution and qualitative inspection of the MS data. For instance, H3K36me2 has a faster half-maximal time than H3K9me2. Our modeling efforts reveal that this behavior is due to the greater rate of dimethylation ($k_{1\rightarrow2}$ and $k'_{1\rightarrow2}$), demethylation ($k_{2\rightarrow1}$), and degradation ($\mu_2$) of H3K36me2 than H3K9me2 (Table 2). Stated differently, H3K36me2 is more rapidly formed and reformed after demethylation than H3K9me2, indicating that H3K36me2 has faster turnover than H3K9me2.

Similar logic applies within a residue, such as H3K9. H3K9me1 is methylated faster ($k_{0\rightarrow1}$ and $k'_{0\rightarrow1}$) than H3K9me2 ($k_{1\rightarrow2}$ and $k'_{1\rightarrow2}$), which is methylated faster than H3K9me3 ($k_{2\rightarrow3}$ and $k'_{2\rightarrow3}$). Although H3K9me1 and H3K9me2 have similar rates of demethylation ($k_{1\rightarrow0}$ and $k_{2\rightarrow3}$) and degradation ($\mu_1$ and $\mu_2$), both have faster rates than H3K9me3 ($k_{3\rightarrow2}$ and $\mu_3$). The net effect is that increasing methylation states on H3K9 have slower turnover. Additionally, for H3K79, there appears to be little detectable demethylation ($k_{1\rightarrow0}$ and $k_{2\rightarrow1}$). Interestingly, there is currently no known demethylase for H3K79 (47). In contrast, although no known demethylase exists for H4K20 (47), our modeling identified a non-zero demethylation rate ($k_{2\rightarrow1}$ and $k_{3\rightarrow2}$) for this site.

In summary, the quantification of all labeled intermediates for each methylation state at each residue allowed fitting of the data to idealized differential equations; these data provide a more complete picture of how actively regulated the histone PTMs are in vivo. Application of the findings and methods of this report provide a platform for further investigation into the dynamic regulation of histone PTMs under varying physiological conditions and over various genomic loci, an understudied yet highly informative part of histone biology and epigenetics.

**Acknowledgments—**We thank Joshua Bloom, R. Scott McIsaac, Fred M. Hughson, Thomas Gregor, John D. Storey, and Joshua D. Rabinowitz for helpful discussion, Robert Endres for supplying an early MATLAB code, and all members of the Garcia laboratory for technical assistance and enlightening conversations.

**REFERENCES**

1. Kouzarides, T. (2007) Cell **128**, 693–705
2. Martin, C., and Zhang, Y. (2005) Nat. Rev. Mol. Cell Biol. **6**, 838–849
3. Rice, J. C., Briggs, S. D., Uebereide, B., Barber, C. M., Shabanowitz, J., Hunt, D. F., Shinkai, Y., and Allis, C. D. (2003) Mol. Cell **12**, 1591–1598
4. Yamane, K., Toumazou, C., Tsukada, Y., Erdjument-Bromage, H., Tempst, P., Wong, J., and Zhang, Y. (2006) Cell **125**, 483–495
5. Klose, R. J., Yamane, K., Bae, Y., Zhang, D., Erdjument-Bromage, H., Tempst, P., Wong, J., and Zhang, Y. (2006) Nature **442**, 312–316
6. Noma, K., Allis, C. D., and Grewal, S. I. (2001) Science **293**, 1150–1155
7. Wang, H., Huang, Z. Q., Xia, L., Feng, Q., Erdjument-Bromage, H., Strahl, B. D., Briggs, S. D., Allis, C. D., Wong, J., Tempst, P., and Zhang, Y. (2001) Science **293**, 853–857
8. Kirmizis, A., Santos-Rosa, H., Penkett, C. J., Singer, M. A., Green, R. D., and Kouzarides, T. (2009) Nat. Struct. Mol. Biol. **16**, 449–451
9. Shi, Y., and Whetstine, J. R. (2007) Mol. Cell **25**, 1–14
10. Waterborg, J. H. (1993) J. Biol. Chem. **268**, 4918–4921
11. Byroo, P., Shepherd, G. R., Hardin, J. M., and Noland, B. J. (1972) Arch. Biochem. Biophys. **148**, 558–567
12. Thomas, G., Lange, H. W., and Hempel, K. (1975) Eur. J. Biochem. **51**, 609–615
13. Pesavento, J. J., Yang, H., Kelleher, N. L., and Mizzen, C. A. (2008) Mol. Cell Biol. **28**, 468–486
14. McManus, K. J., Biron, V. L., Heit, R., Underhill, D. A., and Hendzel, M. J. (2006) J. Biol. Chem. **281**, 8888–8897
15. Scharf, A. N., Barth, T., and Imhof, A. (2009) Nucleic Acids Res. 1–9
16. Morillon, A., Karabetsou, N., Nair, A., and Mellor, J. (2005) Mol. Cell **18**, 723–734
Histone Methylation Dynamics Studied by MS

17. Ong, S., Mittler, G., and Mann, M. (2004) *Nat. Methods* **1**, 1–8
18. Trojer, P., Li, G., Sims, R. J., 3rd, Vaquero, A., Kalakonda, N., Boccuni, P., Lee, D., Erdjument-Bromage, H., Tempst, P., Nimer, S. D., Wang, Y. H., and Reinberg, D. (2007) *Cell* **129**, 915–928
19. Garcia, B. A., Pesavento, J. J., Mizzen, C. A., and Kelleher, N. L. (2007) *Nat. Methods* **4**, 487–489
20. Garcia, B. A., Mollah, S., Ueberheide, B. M., Busby, S. A., Muratore, T. L., Shabanowitz, J., and Hunt, D. F. (2007) *Nat. Cell Biol.* **6**, 459–468
21. LeRoy, G., Weston, J. T., Zee, B. M., Young, N. L., Plazas-Mayorca, M. D., and Garcia, B. A. (2009) *Mol. Cell. Proteomics* **8**, 2432–2442
22. Beisel, C., Imhof, A., Greene, J., Kremmer, E., and Sauer, F. (2002) *Nature* **419**, 857–862
23. Osley, M. A. (1991) *Annu. Rev. Biochem.* **60**, 827–861
24. Worcel, A., Han, S., and Wong, M. L. (1978) *Cell* **15**, 969–977
25. Sirotkin, A. M., Edelmann, W., Cheng, G., Klein-Szanto, A., Kucherlapati, R., and Skoultchi, A. I. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 6434–6438
26. Misteli, T., Gunjan, A., Hock, R., Bustin, M., and Brown, D. T. (2000) *Nature* **408**, 877–881
27. Djondjurov, L. P., Yancheva, N. Y., and Ivanova, E. C. (1983) *Biochemistry* **22**, 4095–4102
28. Oda, Y., Huang, K., Cross, F. R., Cowburn, D., and Chait, B. T. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 6591–6596
29. Fodor, B. D., Kubicek, S., Yonezawa, M., O'Sullivan, R. J., Sengupta, R., Perez-Burgos, L., Opravil, S., Mechtler, K., Schotta, G., and Jenuwein, T. (2009) *Genes Dev.* **20**, 1557–1562
30. Patnaik, D., Chin, H. G., Estève, P., Benner, J., Jacobsen, S. E., and Pradhan, S. (2004) *J. Biol. Chem.* **279**, 53248–53258
31. Trievel, R. C., Beach, B. M., Dirk, L. M., Houtz, R. L., and Hurley, J. H. (2002) *Cell* **111**, 91–103
32. Chin, H. G., Patnaik, D., Estève, P., Jacobsen, S. E., and Pradhan, S. (2006) *Biochemistry* **45**, 3272–3284
33. Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., and Zhao, K. (2007) *Cell* **129**, 823–837
34. Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., Reinberg, D., and Jenuwein, T. (2004) *Genes Dev.* **18**, 1251–1262
35. Plath, K., Fang, J., Mlynarczyk-Evans, S. K., Cao, R., Worringer, K. A., Wang, H., de la Cruz, C. C., Otte, A. P., Panning, B., and Zhang, Y. (2003) *Science* **300**, 131–135
36. Peters, A. H., Kubicek, S., Mechtler, K., O'Sullivan, R. J., Derijck, A. A., Perez-Burgos, L., Kohlmaier, A., Opravil, S., Tachibana, M., Shinkai, Y., Martens, J. H., and Jenuwein, T. (2003) *Mol. Cell* **12**, 1577–1589
37. Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., Jaenisch, R., Wagschal, A., Feil, R., Schreiber, S. L., and Lander, E. S. (2006) *Cell* **125**, 315–326
38. Lee, B. M., and Mahadevan, L. C. (2009) *J. Cell. Biochem.* **108**, 22–34
39. Kurdzistani, S. K., Tavazoie, S., and Grunstein, M. (2004) *Cell* **117**, 715–733
40. Fischle, W., Wang, Y., and Allis, C. D. (2003) *Science* **295**, 475–479
41. Mito, Y., Henikoff, J. G., and Henikoff, S. (2007) *Science* **315**, 1319–1322
42. Forneris, F., Binda, C., Dall’Aglio, A., Fraaije, M. W., Battaglioni, E., and Mattevi, A. (2006) *J. Biol. Chem.* **281**, 35289–35295
43. Luger, K., Máder, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J. (1997) *Nature* **389**, 251–260
44. Boyne, M. T., Garcia, B. A., Li, M., Zamdborg, L., Weng, C. D., Babai, S., and Kelley, N. L. (2009) *J. Proteome Res.* **8**, 374–379
45. Jenuwein, T., and Allis, C. D. (2001) *Science* **293**, 1074–1080
46. Tamaru, H., Zhang, X., McMullen, D., Singh, P. B., Nakayama, J., Grewal, S. I., Allis, C. D., Cheng, X., and Selker, E. U. (2003) *Nat. Genetics* **34**, 75–79
47. Lan, F., and Shi, Y. (2009) *Science in China Series C: Life Sciences* **52**, 311–322
48. Bell, O., Wirbelauer, C., Hild, M., Scharf, A. N., Schweiger, M., MacAlpine, D. M., Zilbermann, F., and Leeuwen, F., Bell, S. P., Imhof, A., Garza, D., Peters, A. H., and Schübeler, D. (2007) *EMBO J.* **26**, 4974–4984
49. Steger, D. J., Lefferova, M. I., Ying, L., Stonestrom, A. J., Schupp, M., Zhuo, D., Yakov, A. L., Kim, J. E., Chen, J., Lazor, M. A., Blobel, G. A., and Vakoc, C. R. (2008) *Mol. Cell. Biol.* **28**, 2825–2839